Skip to content

Menu

LexBlog, Inc. logo
NetworkSub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupportContact
Search
Close

Marks For Hemp and Cannabis

By Rachel B. Rudensky on May 10, 2019
Email this postTweet this postLike this postShare this post on LinkedIn

The United States Patent and Trademark Office recently issued a new Examination Guide relating to trademarks for cannabis and cannabis-related goods and services.

This much-anticipated guide comes after the December 20, 2018 enactment of the Farm Bill. 

Until now, USPTO Trademark Examining Attorneys have had little guidance on how to treat trademark applications for cannabis-related goods.  Though the USPTO never approved trademarks for goods that violated the Controlled Substances Act (“CSA”), there was some confusion concerning trademarks for hemp-derived products after the enactment of the 2018 Farm Bill.  The CSA defines “hemp” as “the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol [THC] concentration of not more than 0.3 percent on a dry weight basis.”  The 2018 Farm Bill removed “hemp” from the CSA’s definition of marijuana, which means that cannabis plants and derivatives such as cannabidiol (CBD) that contain no more than 0.3% THC on a dry-weight basis are no longer controlled substances under the CSA.

After passage of the 2018 Farm Bill, Trademark Examining Attorneys sometimes believed that goods derived from industrial hemp and derivatives of hemp including CBD were lawful, and that they were able to approve trademarks for such goods.  The new Examination Guide basically affirms this.

There is a big caveat, however.  Trademark applicants should be aware that even if the identified goods are legal under the CSA, the 2018 Farm Bill explicitly preserved U.S. Food and Drug Administration’s (FDA) authority to regulate products containing cannabis or cannabis-derived compounds under the Federal Food Drug and Cosmetic Act (FDCA).  The new Examination Guide notes that the use of CBD in foods or dietary supplements of a drug or substance undergoing clinical investigations without approval of the FDA violates the FDCA.  CBD is an active ingredient in FDA-approved drugs and is a substance undergoing clinical investigations.

Therefore, registration of marks for foods, beverages, dietary supplements, or pet treats containing CBD will still be refused as unlawful under the FDCA, even if derived from hemp, as such goods may not be introduced lawfully into interstate commerce.

This change to the examination process should help some applicants to obtain registration for their marks associated with hemp-related goods and services (including hemp-derived CBD), but applicants should carefully consider how the USPTO requirements will affect their trademark rights before taking advantage of the opportunity to obtain their registrations.

Photo of Rachel B. Rudensky Rachel B. Rudensky

Rachel Rudensky assists her clients in all facets of brand development around the world. She represents clients in a wide variety of sectors including, fashion, entertainment, hospitality, professional sports, healthcare, financial services, and consumer goods. Her practice encompasses trademarks, copyrights, and internet disputes…

Rachel Rudensky assists her clients in all facets of brand development around the world. She represents clients in a wide variety of sectors including, fashion, entertainment, hospitality, professional sports, healthcare, financial services, and consumer goods. Her practice encompasses trademarks, copyrights, and internet disputes involving domain names.

Read more about Rachel B. RudenskyEmail
Show more Show less
  • Posted in:
    Cannabis, Intellectual Property
  • Blog:
    Marks, Works, and Secrets
  • Organization:
    Akerman LLP

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS
The Library at LexBlog
  • About LexBlog
  • The Field We Built
  • Library at LexBlog
  • Our Beliefs
  • Our Team
  • Contact LexBlog
  • Disclaimer
  • Editorial Policy
  • Terms of Service
  • Get Started
  • Publishing Solutions
  • Compass
  • Submit a Request
  • Support Center
  • System Status
Copyright © 2026, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo